<DOC>
	<DOCNO>NCT02536300</DOCNO>
	<brief_summary>This study optimize safety efficacy chronic administration idelalisib participant follicular lymphoma ( FL ) evaluate overall safety profile idelalisib overall response rate ( ORR ) Week 24 .</brief_summary>
	<brief_title>Dose Optimization Study Idelalisib Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Key Histologically confirm diagnosis Bcell follicular lymphoma ( FL ) , grade limited 1 , 2 , 3a base criterion establish WHO 2008 classification tumor hematopoietic lymphoid tissue Refractory disease progression within 6 month last dose least 2 line prior therapy AnnArbor Stage 2 ( noncontiguous ) , 3 , 4 disease per Lugano Classification Radiographically measurable lymphadenopathy extranodal lymphoid malignancy ( define presence ≥ 1 lesion measure ≥ 1.5 cm long dimension ( LD ) ≥ 1.0 cm long perpendicular dimension ( LPD ) assess positron emission tomographycomputed tomography ( PETCT ) , compute tomography ( CT ) magnetic resonance imaging ( MRI ) Required baseline central laboratory data protocol . For female individual childbearing potential male individual reproductive potential , willingness use protocol recommend method contraception Lactating female must agree discontinue nurse Willing able comply schedule visit , drug administration plan , image study , laboratory test , study procedure , study restriction include mandatory prophylaxis Pneumocystis jirovecii pneumonia ( PJP ) Key History lymphoid malignancy FL ( eg , diffuse large Bcell lymphoma ) Known history , clinically apparent , central nervous system ( CNS ) lymphoma leptomeningeal lymphoma . Known presence intermediate highgrade myelodysplastic syndrome . Known history serious allergic reaction include anaphylaxis Stevens Johnson syndrome/ toxic epidermal necrolysis History nonlymphoid malignancy except protocol allow exception Evidence ongoing systemic bacterial , fungal , viral infection time enrollment Known history druginduced liver injury , chronic active hepatitis B virus ( HBV ) , chronic active hepatitis C virus ( HCV ) , alcoholic liver disease , nonalcoholic steatohepatitis , cirrhosis liver , portal hypertension , primary biliary cirrhosis , ongoing extrahepatic obstruction cause cholelithiasis History ongoing druginduced pneumonitis History ongoing inflammatory bowel disease Known human immunodeficiency virus ( HIV ) infection History prior allogeneic bone marrow progenitor cell solid organ transplantation Ongoing immunosuppressive therapy , include systemic corticosteroid ( &gt; 10 mg prednisone equivalent/day ) exception use topical , enteric , inhaled corticosteroid therapy comorbid condition systemic steroid autoimmune anemia and/or thrombocytopenia Concurrent participation another therapeutic clinical trial Prior treatment phosphatidylinositol 3kinase ( PI3K ) delta inhibitor , Bruton 's tyrosine kinase ( BTK ) inhibitor , janus kinase inhibitor ( JAK ) inhibitor , mammalian target rapamycin ( mTOR ) inhibitor , spleen tyrosine kinase ( Syk ) inhibitor Cytomegalovirus ( CMV ) Ongoing infection , treatment , prophylaxis within past 28 day NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>